Vice President of Investor Relations & Corporate Communications
Janux Therapeutics
Vice President of Investor Relations & Corporate Communications
Janux Therapeutics
Clinical-stage biotech developing tumor-activated immunotherapies
Salary Range: 317000 to 347000 (Currency: USD) (Pay period: per-year-salary)
Janux Therapeutics is seeking a seasoned and strategic Vice President of Investor Relations & Corporate Communications to lead the company’s external engagement across the investment community, media, and broader public audiences. This role is instrumental in shaping Janux’s corporate narrative and ensuring transparent, consistent, and impactful communication of the company’s scientific progress, financial performance, and strategic priorities, supporting long-term value creation.
The incumbent will report directly to the Chief Corporate and Business Development Officer, and collaborate closely with the CEO, Legal, and other senior stakeholders. The Vice President will serve as a key advisor to executive leadership and the Board on investor sentiment, shareholder communications, market positioning, and sensitive public-facing decisions. This role demands a seasoned communicator with deep capital markets expertise, a sophisticated understanding of the biotech landscape, and the ability to translate complex scientific and business developments into compelling narratives that resonate with diverse external audiences.
Clinical-stage biotech developing tumor-activated immunotherapies
Janux Therapeutics develops cancer immunotherapies that activate the immune system inside tumors to attack cancer while sparing healthy tissue. Its products are tumor-activated and use a proprietary platform masking technology to reduce toxic side effects and improve efficacy compared with traditional T cell engagers. The company advances drug candidates through clinical trials, aiming for regulatory approval and eventual commercialization, with revenue expected from partnerships, licensing, and the sale of approved therapies. Its lead program JANX007 is being evaluated in a Phase 1 trial (ENGAGER PSMA 01) for metastatic prostate cancer to assess safety and preliminary effectiveness.
Explore more opportunities at Janux Therapeutics